Riskpilot← Back to searchSign inGet full accessMuna Therapeutics ApS
APSActiveCVR 41142871Nordre Fasanvej 215Manufacture of pharmaceutical preparations · NACE 2120Est. 202020 employees
Revenue 2024
DKK -124,7M
+13% vs 2023
EBITDA margin
123.2%
-13% vs 2023
Equity ratio
10.7%
Financial strength
Net profit 2024
DKK -173,6M
-24% vs 2023
| Revenue | DKK -124,7M | +13% |
| EBITDA | DKK -153,7M | -13% |
| Net profit | DKK -173,6M | -24% |
| Total assets | DKK 175M | +4% |
| Equity | DKK 18,7M | -85% |
| Employees | 20 | — |
Legal name
Muna Therapeutics ApS
CVR number
41142871
Legal form
Anpartsselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
22. januar 2020
Share capital
DKK 1.342.945
Employees
20 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af bestyrelsesformanden i forening med et bestyrelsesmedlem, eller af bestyrelsesformanden
i forening med en direktør eller af den samlede bestyrelse.
Company purpose
Selskabets formål er at forske i, udvikle, producere og sælge bioteknologiske produkter
og medicinalprodukter samt anden virksomhed, der efter ledelsens skøn er forbundet dermed.
Address
Nordre Fasanvej 215
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | -7.345 | -49.693 | -98.234 | -110.624 | -124.746 |
| Staff expenses | -2.842 | -8.756 | -20.426 | -25.334 | -28.780 |
| EBITDA | -10.187 | -58.449 | -118.660 | -135.959 | -153.651 |
| Depreciation & amort. | -0 | -3.020 | -3.790 | -6.559 | -10.073 |
| EBIT | -10.187 | -61.469 | -122.450 | -142.518 | -163.723 |
| Net financials | -44 | -4.914 | -10.732 | -3.233 | -4.889 |
| Profit before tax | -10.231 | -66.383 | -133.182 | -145.751 | -168.612 |
| Tax | -2.849 | -4.865 | -5.500 | -5.431 | 5.013 |
| Net profit | -7.382 | -61.518 | -127.682 | -140.320 | -173.625 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 24.321 | 184.064 | 247.518 | 168.210 | 175.026 |
| Equity | 16.658 | 162.313 | 202.045 | 126.960 | 18.713 |
| Long-term debt | 43 | 0 | 16 | 0 | 108.080 |
| Short-term debt | 7.621 | 21.751 | 45.433 | 41.251 | 48.233 |
| Total debt | 7.663 | 21.751 | 45.449 | 41.251 | 156.313 |
EBITDA margin
-15365058800.0%
This company
15.8%
Market median
-97247207695% vs market
20202024
Equity ratio
10.7%
This company
38.2%
Market median
-72% vs market
20202024
Return on equity
-927.8%
This company
18.4%
Market median
-5142% vs market
20202024
Net profit margin
-17362535700.0%
This company
8.1%
Market median
-214352292693% vs market
20202024
Asset turnover
-0.71×
This company
1.12×
Market median
-163% vs market
20202024
Debt / equity
8.35×
This company
0.62×
Market median
-1247% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-22 – 2020-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
JP Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
AM Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2020 | — | — | |
| Chairman | 2020 | — | — | |
| Chairman | 2021 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2020 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Novo Holdings A/S | Company | 15.0% | 15.0% | 2023 |
| Individual | 15.0% | 15.0% | 2022 | |
| Individual | 15.0% | 15.0% | 2021 | |
| Individual | 5.0% | 5.0% | 2021 | |
| Individual | 5.0% | 5.0% | 2022 | |
| Individual | 5.0% | 5.0% | 2022 | |
| Individual | 5.0% | 5.0% | 2021 | |
| Individual | 5.0% | 5.0% | 2021 | |
WoB Holding ApS | Company | 10.0% | 10.0% | 2020 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
NOVO NORDISK FONDEN
Muna Therapeutics ApS Board members of Muna Therapeutics ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Joachim Pold Vilstrup | Chief Executive Officer | 0 companies |
| Anders Mørkeberg Hinsby | Chief Executive Officer | 0 companies |
| Peder Søndergaard Madsen | Chairman | 0 companies |
| Morten Døssing | Chairman | 0 companies |
| Donald William Nicholson | Chairman | 0 companies |
| Luc Dochez | Board of Directors | 0 companies |
| Luc Madeleine Albert Dochez | Board of Directors | 0 companies |
| Isaac Ciechanover | Board of Directors | 0 companies |
| Simon Glerup Pedersen | Board of Directors | 0 companies |
| Chiara Rossana Maria Liberati | Board of Directors | 0 companies |
| Camilla Petrycer Hansen | Board of Directors | 0 companies |
| Reza Halse | Board of Directors | 0 companies |
| Henrijette Elsebeth Richter | Board of Directors | 0 companies |
| Laia Crespo-Martin | Board of Directors | 0 companies |
| Eileen Elizabeth McGuire | Board of Directors | 0 companies |
| Cillian King | Board of Directors | 0 companies |
| Stefan Lohmer | Board of Directors | 0 companies |